Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Trinity Biotech ( (TRIB) ).
On December 23, 2025, Trinity Biotech announced a major order for 9 million units of its WHO-prequalified TrinScreen HIV rapid test, to be produced via its newly WHO-approved outsourced manufacturing process and delivered across the fourth quarter of 2025 and the first quarter of 2026, signaling a strong rebound in global HIV testing demand and reinforcing the company’s positioning in infectious disease diagnostics. In the same update, the company reported a 32% sequential revenue jump to $14.3 million in the third quarter of 2025, improved gross margins to 45.2%, and a return to positive adjusted EBITDA of $0.5 million, highlighted progress under its Comprehensive Transformation Plan, outlined further operational efficiencies and product pipeline advances in diabetes and oncology-related diagnostics, and announced a finance leadership transition as Paul Murphy was promoted to interim chief financial officer following the completion of Susan O’Connor’s interim term.
The most recent analyst rating on (TRIB) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Trinity Biotech stock, see the TRIB Stock Forecast page.
Spark’s Take on TRIB Stock
According to Spark, TipRanks’ AI Analyst, TRIB is a Underperform.
Trinity Biotech’s overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues, negative profitability, and high debt levels. Technical analysis shows mixed signals, with short-term bullish momentum but potential for a pullback. Valuation metrics are unattractive due to negative earnings and lack of dividends.
To see Spark’s full report on TRIB stock, click here.
More about Trinity Biotech
Trinity Biotech plc is a Dublin-based commercial-stage biotechnology company specializing in human diagnostic solutions and diabetes management technologies, including wearable biosensors. The company focuses on infectious disease testing, notably rapid HIV screening, as well as haemoglobin and HbA1c diagnostics, and is expanding its portfolio with products such as next-generation continuous glucose monitoring and advanced screening tests for prostate cancer and preeclampsia aimed at global healthcare markets.
Average Trading Volume: 101,970
Technical Sentiment Signal: Sell
Current Market Cap: $16.25M
See more insights into TRIB stock on TipRanks’ Stock Analysis page.